Technical Analysis for PIRS - Pieris Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.7 -4.26% -0.12
PIRS closed down 4.26 percent on Thursday, January 17, 2019, on 43 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical PIRS trend table...

Date Alert Name Type % Chg
Jan 17 Fell Below 20 DMA Bearish 0.00%
Jan 16 20 DMA Support Bullish -4.26%
Jan 16 Outside Day Range Expansion -4.26%
Jan 14 Overbought Stochastic Strength -5.92%
Jan 11 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -9.40%
Jan 11 Weak + Overbought Other -9.40%
Jan 11 Overbought Stochastic Strength -9.40%
Jan 11 Upper Bollinger Band Touch Strength -9.40%
Jan 10 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -14.01%
Jan 10 20 DMA Support Bullish -14.01%

Older signals for PIRS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of Anticalin class biotherapeutics. Anticalin proteins are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on development of two drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases. It is also developing PRS-110, a monovalent antagonist that is used for the treatment of various types of cancers, including renal, gastric, and lung carcinomas, as well as central nervous system tumors and sarcomas; and PRS-300series of Anticalin proteins in immuno-oncology. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.
Is PIRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.75
52 Week Low 2.39
Average Volume 604,331
200-Day Moving Average 4.9427
50-Day Moving Average 3.1626
20-Day Moving Average 2.768
10-Day Moving Average 2.883
Average True Range 0.2472
ADX 23.04
+DI 18.191
-DI 17.5984
Chandelier Exit (Long, 3 ATRs ) 2.5084
Chandelier Exit (Short, 3 ATRs ) 3.1316
Upper Bollinger Band 3.1213
Lower Bollinger Band 2.4147
Percent B (%b) 0.4
BandWidth 25.527457
MACD Line -0.0944
MACD Signal Line -0.1294
MACD Histogram 0.035
Fundamentals Value
Market Cap 119.63 Million
Num Shares 44.3 Million
EPS -0.71
Price-to-Earnings (P/E) Ratio -3.80
Price-to-Sales 31.97
Price-to-Book 22.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.02
Resistance 3 (R3) 3.04 2.96 2.96
Resistance 2 (R2) 2.96 2.88 2.95 2.94
Resistance 1 (R1) 2.83 2.83 2.79 2.81 2.93
Pivot Point 2.75 2.75 2.73 2.74 2.75
Support 1 (S1) 2.62 2.67 2.58 2.60 2.47
Support 2 (S2) 2.54 2.62 2.53 2.46
Support 3 (S3) 2.41 2.54 2.44
Support 4 (S4) 2.39